Episodios

  • Emerging Potential Treatment Options for Schizophrenia With Negative and Cognitive Symptoms (Part 2)

    Emerging Potential Treatment Options for Schizophrenia With Negative and Cognitive Symptoms (Part 2)
    Jul 16 2024
    Drs. Mattingly and McIntyre continue their discussion about their insights into the role of emerging and novel mechanisms of action for potential treatments of schizophrenia, particularly those addressing the negative and cognitive symptoms.
    Más Menos
    13 m
  • Investigational drug boosts pregnancy rates in women undergoing IVF, ICSI

    Investigational drug boosts pregnancy rates in women undergoing IVF, ICSI
    Jul 16 2024
    Learn about OXO-001, a non-hormonal drug that increases pregnancy rates in women undergoing IVF or ICSI by enhancing embryo implantation. Also in this episode: patients with type 2 diabetes taking GLP-1 receptor agonists have a lower risk of certain obesity-associated cancers compared to those on insulin, though no significant reduction compared to metformin. Finally, the third story highlights research showing that smoking accelerates cognitive decline in memory and fluency, except for smokers with otherwise healthy lifestyles, who experience similar decline rates to non-smokers.
    Más Menos
    5 m
  • Emerging Potential Treatment Options for Schizophrenia With Negative and Cognitive Symptoms (Part 1)

    Emerging Potential Treatment Options for Schizophrenia With Negative and Cognitive Symptoms (Part 1)
    Jul 15 2024
    Drs. Roger McIntyre and Greg Mattingly share their insights into the role of emerging and novel mechanisms of action for potential treatments of schizophrenia, particularly those addressing the negative and cognitive symptoms.
    Más Menos
    14 m
  • Specialist Spotlight: The Role of Assessment and Screening for Cognitive Impairment in Patients With Schizophrenia (Part 2)

    Specialist Spotlight: The Role of Assessment and Screening for Cognitive Impairment in Patients With Schizophrenia (Part 2)
    Jul 12 2024
    In the second part of this series, Drs. Henry A. Nasrallah and Dawn Velligan continue sharing their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn’t more widespread, the barriers clinicians face in testing, and the misconception that testing for cognitive impairment is prohibitive due to the resources required. Finally, they describe time factors and utility of several currently available tests, including those that can be used in busy ambulatory mental healthcare settings.
    Más Menos
    16 m
  • Specialist Spotlight: The Role of Assessment and Screening for Cognitive Impairment in Patients With Schizophrenia (Part 1)

    Specialist Spotlight: The Role of Assessment and Screening for Cognitive Impairment in Patients With Schizophrenia (Part 1)
    Jul 11 2024
    Drs. Dawn Velligan and Henry A. Nasrallah share their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn’t more widespread, the barriers clinicians face in testing, and the misconception that testing for cognitive impairment is prohibitive due to the resources required. Finally, they describe time factors and utility of several currently available tests, including those that can be used in busy ambulatory mental healthcare settings.
    Más Menos
    14 m
  • Specialist Spotlight: Recognizing the Three Symptoms Domains of Schizophrenia in the Outpatient Clinical Practice (Part 2)

    Specialist Spotlight: Recognizing the Three Symptoms Domains of Schizophrenia in the Outpatient Clinical Practice (Part 2)
    Jul 10 2024
    Dr. Gus Alva and Ms. Sheena Patel, PA-C, continue their conversation, sharing insights into the three symptom domains of schizophrenia: positive, negative, and cognitive impairment. They discuss how each of these symptom domains could present in the outpatient clinical practice, with particular focus on negative symptoms and cognitive impairment.
    Más Menos
    12 m
  • FDA approves new drug for early Alzheimer's disease

    FDA approves new drug for early Alzheimer's disease
    Jul 9 2024
    Can a new drug slow the progression of Alzheimer's disease? Find out about this and more in today's PeerDirect Medical News Podcast.
    Más Menos
    5 m
  • Recognizing the Three Symptoms Domains of Schizophrenia in the Outpatient Clinical Practice (Part 1)

    Recognizing the Three Symptoms Domains of Schizophrenia in the Outpatient Clinical Practice (Part 1)
    Jul 8 2024
    Ms. Sheena Patel, PA-C, and Dr. Gus Alva share their insights into the three symptom domains of schizophrenia: positive, negative, and cognitive impairment, and how each of these symptom domains could present in the outpatient clinical practice. In particular, they discuss the less obvious domains: negative symptoms and cognitive impairment.
    Más Menos
    10 m